According to Cardiovascular Systems's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -20.6186. At the end of 2021 the company had a P/E ratio of -25.4.
Year | P/E ratio | Change |
---|---|---|
2021 | -25.4 | -67.44% |
2020 | -77.9 | -66.31% |
2019 | -231 | -132.49% |
2018 | 712 | -400.65% |
2017 | -237 | 751.31% |
2016 | -27.8 | 174.23% |
2015 | -10.1 | -64.24% |
2014 | -28.4 | -2.35% |
2013 | -29.1 | 133.86% |
2012 | -12.4 | -5.39% |
2011 | -13.1 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.2 | -154.39% | ๐บ๐ธ USA |
Medtronic MDT | 32.0 | -254.99% | ๐ฎ๐ช Ireland |
Boston Scientific BSX | 83.7 | -505.86% | ๐บ๐ธ USA |
Merit Medical MMSI | 43.4 | -310.33% | ๐บ๐ธ USA |
LeMaitre Vascular LMAT | 54.6 | -364.97% | ๐บ๐ธ USA |
AngioDynamics ANGO | 35.6 | -272.78% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.